Childhood cerebral astrocytoma
diseaseOn this page
Also known as cerebral astrocytomacerebral astrocytoma, childhoodchildhood astrocytic tumor of telencephalonchildhood astrocytic tumour of telencephalonchildhood astrocytoma of cerebrumchildhood astrocytoma of the cerebrumpaediatric astrocytoma of cerebrumpaediatric astrocytoma of the cerebrumpaediatric cerebral astrocytomapediatric astrocytoma of cerebrumpediatric astrocytoma of the cerebrumpediatric cerebral astrocytomatelencephalon childhood astrocytic tumortelencephalon childhood astrocytic tumourtelencephalon juvenile astrocytoma
Summary
Childhood cerebral astrocytoma (MONDO:0004071) is a disease and 24 clinical trials. Top therapeutic interventions include bevacizumab, edotreotide gallium ga-68, and fluorodopa f 18. A subtype of childhood astrocytic tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 24
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | childhood cerebral astrocytoma |
| Mondo ID | MONDO:0004071 |
| DOID | DOID:7007 |
| NCIT | C4347 |
| UMLS | C0338070 |
| MedGen | 137828 |
| GARD | 0009302 |
| Anatomy (UBERON) | UBERON:0001893 |
| Is cancer (heuristic) | no |
Also known as: cerebral astrocytoma · cerebral astrocytoma, childhood · childhood astrocytic tumor of telencephalon · childhood astrocytic tumour of telencephalon · childhood astrocytoma of cerebrum · childhood astrocytoma of the cerebrum · paediatric astrocytoma of cerebrum · paediatric astrocytoma of the cerebrum · paediatric cerebral astrocytoma · pediatric astrocytoma of cerebrum · pediatric astrocytoma of the cerebrum · pediatric cerebral astrocytoma · telencephalon childhood astrocytic tumor · telencephalon childhood astrocytic tumour · telencephalon juvenile astrocytoma
Disease family
This is a subtype of childhood astrocytic tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › childhood neoplasm › childhood astrocytic tumor › childhood cerebral astrocytoma
Related subtypes (3): childhood cerebellar astrocytic neoplasm, childhood brainstem astrocytoma, childhood pilocytic astrocytoma
Subtypes (1): childhood optic tract astrocytoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 24.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 15 |
| PHASE2 | 5 |
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01236560 | PHASE2/PHASE3 | COMPLETED | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma |
| NCT00004078 | PHASE2 | COMPLETED | Irinotecan in Treating Children With Refractory Solid Tumors |
| NCT00070525 | PHASE2 | COMPLETED | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma |
| NCT00091182 | PHASE2 | COMPLETED | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment |
| NCT00679354 | PHASE2 | COMPLETED | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy |
| NCT01462695 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma |
| NCT00012181 | PHASE1 | COMPLETED | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas |
| NCT00052780 | PHASE1 | COMPLETED | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors |
| NCT00053963 | PHASE1 | COMPLETED | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia |
| NCT00063973 | PHASE1 | COMPLETED | Cilengitide in Treating Children With Refractory Primary Brain Tumors |
| NCT00077454 | PHASE1 | COMPLETED | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors |
| NCT00100880 | PHASE1 | COMPLETED | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors |
| NCT00101270 | PHASE1 | COMPLETED | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
| NCT00326664 | PHASE1 | COMPLETED | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors |
| NCT00363272 | PHASE1 | COMPLETED | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma |
| NCT00638898 | PHASE1 | COMPLETED | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
| NCT00946335 | PHASE1 | COMPLETED | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors |
| NCT00994500 | PHASE1 | COMPLETED | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
| NCT01076530 | PHASE1 | COMPLETED | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
| NCT02255461 | PHASE1 | TERMINATED | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors |
| NCT00919750 | Not specified | COMPLETED | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors |
| NCT02175745 | Not specified | TERMINATED | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas |
| NCT02194452 | Not specified | WITHDRAWN | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 1 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| FLUORODOPA F 18 | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| TEMOZOLOMIDE | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| ALVOCIDIB | 3 | 3 |
| CILENGITIDE | 3 | 2 |
| VELIPARIB | 3 | 2 |
| 6-O-BENZYLGUANINE | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| TIPIFARNIB | 3 | 1 |
| ISPINESIB | 2 | 1 |
| CHEMBL4228794 | 0 | 1 |
| CHEMBL4248195 | 0 | 1 |
| CHEMBL541887 | 0 | 1 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL4066465 | 0 | 1 |
| CHEMBL2326523 | 0 | 1 |